Icotinib: kick-starting the Chinese anticancer drug industry
Author:
Publisher
Elsevier BV
Subject
Oncology
Reference5 articles.
1. Icotinib versus gefitinib in previously treated advanced non-small-cell lung cancer (ICOGEN): a randomised, double-blind phase 3 non-inferiority trial;Shi;Lancet Oncol,2013
2. Epidermal growth factor receptor mutations in lung cancer;Sharma;Nat Rev Cancer,2007
3. Spectrum of oncogenic driver mutations in lung adenocarcinomas from East Asian never smokers;Li;PLoS One,2011
4. Gefitinib or carboplatin-paclitaxel in pulmonary adenocarcinoma;Mok;N Engl J Med,2009
Cited by 20 articles. 订阅此论文施引文献 订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献
1. EGFR/HER Family Inhibitors;Molecules Engineered Against Oncogenic Proteins and Cancer;2023-09-08
2. Anticancer drugs acting on signaling pathways, part 1: Tyrosine kinase inhibitors;Medicinal Chemistry of Anticancer Drugs;2023
3. Landscape of the clinical development of China innovative anti-lung cancer drugs;Cancer Pathogenesis and Therapy;2023-01
4. And Still They Come Over Troubled Waters: Can Asia’s Third-Generation EGFR Tyrosine Kinase Inhibitors (Furmonertinib, Aumolertinib, Rezivertinib, Limertinib, Befotertinib, SH-1028, and Lazertinib) Affect Global Treatment of EGFR+ NSCLC;Journal of Thoracic Oncology;2022-10
5. The changing landscape of anti-lung cancer drug clinical trials in mainland China from 2005 to 2020;The Lancet Regional Health - Western Pacific;2021-06
1.学者识别学者识别
2.学术分析学术分析
3.人才评估人才评估
"同舟云学术"是以全球学者为主线，采集、加工和组织学术论文而形成的新型学术文献查询和分析系统，可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容，当前同舟云学术共收录了国内外主流学术期刊6万余种，收集的期刊论文及会议论文总量共计约1.5亿篇，并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询！咨询电话：010-8811{复制后删除}0370
www.globalauthorid.com
TOP
Copyright © 2019-2024 北京同舟云网络信息技术有限公司 京公网安备11010802033243号 京ICP备18003416号-3